Placebo in 1 capsule contains 250 mg microcrystalline cellulose and other compounds including colloidal silicon dioxide&#44

2 trials

Sponsors

Government Pharmaceutical Organization (GPO)

Conditions

1. Gastroesophageal reflux disease (GERD) 2. functional dyspepsia curcuminoid gastroesophageal reflux gastric emptying gastric accommodationGastroesophageal reflux disease (GERD) and acid reflux in the esophagus is excessive. curcuminoid&#44

Phase 2

The effects of curcuminoid on esophageal and gastric function in patients with gastroesophageal reflux disease

Active, not recruitingTCTR20180530008

Government Pharmaceutical Organization (GPO)Gastroesophageal reflux disease (GERD) and acid reflux in the esophagus is excessive. curcuminoid&#44

Start: 2018-03-01Target: 20Updated: 2026-03-30

The efficacy of curcuminoid in patients with overlapping gastroesophageal reflux disease and functional dyspepsia: A randomized controlled trial.

Active, not recruitingTCTR20180530003

Government Pharmaceutical Organization (GPO)1. Gastroesophageal reflux disease (GERD) 2. functional dyspepsia curcuminoid gastroesophageal reflux gastric emptying gastric accommodation

Start: 2018-03-01Target: 86Updated: 2026-03-30